William Richard White Sells 1,634 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CFO William Richard White sold 1,634 shares of the stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $54.84, for a total transaction of $89,608.56. Following the sale, the chief financial officer now directly owns 57,521 shares in the company, valued at $3,154,451.64. This trade represents a 2.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Richard White also recently made the following trade(s):

• On Tuesday, June 10th, William Richard White sold 2,804 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.99, for a total value of $151,387.96.

Akero Therapeutics Trading Down 1.3%

Shares of Akero Therapeutics stock traded down $0.70 during trading on Friday, reaching $54.20. 1,983,828 shares of the company were exchanged, compared to its average volume of 1,019,471. The business has a 50-day moving average price of $45.88 and a 200-day moving average price of $41.10. The firm has a market capitalization of $4.32 billion, a price-to-earnings ratio of -27.79 and a beta of -0.16. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03. Akero Therapeutics, Inc. has a twelve month low of $21.02 and a twelve month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. Sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in AKRO. Tema Etfs LLC acquired a new stake in Akero Therapeutics during the 4th quarter worth $894,000. Cubist Systematic Strategies LLC bought a new position in Akero Therapeutics in the fourth quarter valued at approximately $840,000. RTW Investments LP boosted its holdings in shares of Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after buying an additional 940,388 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of Akero Therapeutics in the fourth quarter valued at approximately $422,000. Finally, Two Sigma Advisers LP increased its position in shares of Akero Therapeutics by 195.7% during the fourth quarter. Two Sigma Advisers LP now owns 41,100 shares of the company's stock worth $1,143,000 after acquiring an additional 27,200 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Bank of America boosted their target price on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. HC Wainwright lifted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Citigroup dropped their price objective on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.